BioPhy
New drug advances have the potential to solve some of society’s most pressing health issues, but forecasting a drug’s effectiveness can sometimes feel like a shot in the dark. That lack of knowledge often leads investors to back clinical-trial-stage companies with big ambitions that don’t pan out. Steve Truong WG21, Dave Latshaw II WG21, and Dan Sciubba WG21 are helping investors make more informed decisions with proprietary artificial-intelligence technology designed to better predict trial successes. Through its own investing arm, BioPhy is pursuing better returns for its backers and more optimal outcomes for patients.
